Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms

The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs). Quantitative data synthesis was performed using a random-effects mo...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis Vol. 253; pp. 194 - 208
Main Authors: Chruściel, Piotr, Sahebkar, Amirhossein, Rembek-Wieliczko, Magdalena, Serban, Maria-Corina, Ursoniu, Sorin, Mikhailidis, Dimitri P., Jones, Steven R., Mosteoru, Svetlana, Blaha, Michael J., Martin, Seth S., Rysz, Jacek, Toth, Peter P., Lip, Gregory Y.H., Pencina, Michael J., Ray, Kausik K., Banach, Maciej
Format: Journal Article
Language:English
Published: Ireland Elsevier B.V 01.10.2016
Subjects:
Adiponectin
Adiponectin - blood
Adult
Aged
Atorvastatin - therapeutic use
Cardiovascular
Cardiovascular Diseases - blood
Female
Humans
Hydroxymethylglutaryl-CoA reductase inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Male
Meta-analysis
Middle Aged
Pravastatin - therapeutic use
Quinolines - therapeutic use
Randomized Controlled Trials as Topic
Regression Analysis
Rosuvastatin Calcium - therapeutic use
Simvastatin - therapeutic use
Statins
Hydroxymethylglutaryl-CoA reductase inhibitors
Statins
Adiponectin
Meta-analysis
ISSN:0021-9150, 1879-1484, 1879-1484
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs). Quantitative data synthesis was performed using a random-effects model with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. In 30 studies (43 study arms) with 2953 participants, a significant increase in plasma adiponectin levels was observed after statin therapy (WMD: 0.57 μg/mL, 95% CI: 0.18, 0.95, p = 0.004). In subgroup analysis, atorvastatin, simvastatin, rosuvastatin, pravastatin and pitavastatin were found to change plasma adiponectin concentrations by 0.70 μg/mL (95% CI: −0.26, 1.65), 0.50 μg/mL (95% CI: −0.44, 1.45), −0.70 μg/mL (95% CI: −1.08, −0.33), 0.62 μg/mL (95% CI: −0.12, 1.35), and 0.51 μg/mL (95% CI: 0.30, 0.72), respectively. With respect to duration of treatment, there was a significant increase in the subset of trials lasting ≥12 weeks (WMD: 0.88 μg/mL, 95% CI: 0.19, 1.57, p = 0.012) but not in the subset of <12 weeks of duration (WMD: 0.18 μg/mL, 95% CI: −0.23, 0.58, p = 0.390). Random-effects meta-regression suggested a significant association between statin-induced elevation of plasma adiponectin and changes in plasma low density lipoprotein cholesterol levels (slope: 0.04; 95% CI: 0.01, 0.06; p = 0.002). The meta-analysis showed a significant increase in plasma adiponectin levels following statin therapy. Although statins are known to increase the risk for new onset diabetes mellitus, our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression. [Display omitted] •The effect of statin therapy on plasma adiponectin levels has not been conclusively studied.•The analysis shows a significant increase in plasma adiponectin levels after statin therapy (WMD: +0.57 μg/mL).•The meta-analysis confirmed that statins may have an important impact on the adiponectin levels.•The pleiotropic adiponectin-elevating effect of statins might explain the benefits of statins in reducing the CV risk.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
ISSN:0021-9150
1879-1484
1879-1484
DOI:10.1016/j.atherosclerosis.2016.07.897